DCT

1:26-cv-01101

Organon LLC v. Encube Ethicals Ltd

Log In
Key Events
Complaint
complaint Intelligence

I. Executive Summary and Procedural Information

  • Parties & Counsel:
  • Case Identification: 1:26-cv-01101, D. Del., 09/01/2026
  • Venue Allegations: Plaintiffs allege venue is proper in the District of Delaware based on Defendant's purposeful and systematic contacts with the state, the assertion that the district will be a destination for the accused product, and Defendant's previous litigation conduct in the district, including asserting counterclaims without challenging personal jurisdiction.
  • Core Dispute: Plaintiffs allege that Defendant's filing of an Abbreviated New Drug Application (ANDA) to market a generic version of Plaintiffs' VTAMA® (tapinarof) cream constitutes an act of infringement of thirteen U.S. patents.
  • Technical Context: The patents relate to pharmaceutical compositions, manufacturing processes, and methods of use for tapinarof, a novel topical therapeutic for treating inflammatory skin diseases such as plaque psoriasis and atopic dermatitis.
  • Key Procedural History: The complaint notes that Defendant previously filed an inter partes review (IPR) petition against U.S. Patent No. 11,590,088. Following institution by the Patent Trial and Appeal Board (PTAB), Plaintiff Dermavant Sciences GmbH filed a disclaimer for all challenged claims, leading to the conclusion of the IPR. The complaint emphasizes that the claims asserted in the present litigation were not challenged in that IPR.

Case Timeline

Date Event
2012-01-01 GlaxoSmithKline acquires rights to tapinarof (approximate date)
2015-05-21 Earliest Priority Date for '160, '743, '108, '573, '724, '945 Patents
2017-11-10 Earliest Priority Date for '649, '718, '088, '692, '099, '453 Patents
2018-01-01 GlaxoSmithKline sells rights to Dermavant (approximate date)
2019-02-05 U.S. Patent No. 10,195,160 Issues
2019-10-01 U.S. Patent No. 10,426,743 Issues
2020-05-12 U.S. Patent No. 10,647,649 Issues
2022-05-23 VTAMA receives FDA approval for plaque psoriasis
2022-10-04 U.S. Patent No. 11,458,108 Issues
2022-11-15 U.S. Patent No. 11,497,718 Issues
2023-02-28 U.S. Patent No. 11,590,088 Issues
2023-03-07 U.S. Patent No. 11,597,692 Issues
2023-03-28 U.S. Patent No. 11,612,573 Issues
2023-04-04 U.S. Patent No. 11,617,724 Issues
2023-04-11 U.S. Patent No. 11,622,945 Issues
2024-01-01 Organon acquires Dermavant (approximate date)
2024-03-26 U.S. Patent No. 11,938,099 Issues
2024-04-23 Encube files IPR petition against the '088 Patent
2024-11-08 PTAB institutes IPR against the '088 Patent
2024-12-12 VTAMA receives FDA approval for atopic dermatitis
2025-01-28 Dermavant disclaims challenged claims of the '088 Patent
2025-12-01 FDA Draft Guidance on Tapinarof published (approximate date)
2026-03-10 U.S. Patent No. 12,569,453 Issues
2026-07-21 Encube sends Notice Letter to Organon
2026-09-01 Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 10,195,160 - "Topical pharmaceutical compositions"

  • Patent Identification: U.S. Patent No. 10,195,160, titled "Topical pharmaceutical compositions," issued on February 5, 2019 (the "'160 Patent").

The Invention Explained

  • Problem Addressed: The patent addresses the challenge of creating a topical pharmaceutical composition for the active ingredient tapinarof (3,5-Dihydroxy-4-isopropyl-trans-stilbene) that is both physically and chemically stable, as the compound is known to be sensitive to oxidation and photo-degradation Compl. Ex. 1, col. 1:12-24 Compl. Ex. 1, col. 1:61-64
  • The Patented Solution: The invention is a topical pharmaceutical emulsion that solves the stability problem by creating a homogenous composition where the active ingredient is solubilized in the oil phase Compl. Ex. 1, abstract The specification contrasts this with prior unstable formulations that developed non-uniform, "waxy" regions, illustrating the technical solution achieved Compl. Ex. 1, col. 2:8-12 Compl. Ex. 1, FIG. 1 Compl. Ex. 1, FIG. 2
  • Technical Importance: This approach enabled the creation of a stable, commercially viable topical cream that could effectively deliver a therapeutically promising but unstable molecule for treating skin conditions.

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '160 Patent Compl. ¶45
  • Independent claim 1 recites:
    • A topical pharmaceutical oil-in-water emulsion composition comprising: 3,5-dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof;
    • an oil phase comprising medium chain triglycerides of a carbon length from six to twelve carbons;
    • a water phase;
    • a surfactant; and
    • a dermatologically acceptable excipient;
    • wherein the 3,5-dihydroxy-4-isopropyl-trans-stilbene is solubilized in the oil phase and is the only active ingredient in the oil phase;
    • wherein the oil phase is substantially free of petrolatum and mineral oil;
    • wherein the oil-in-water emulsion is homogeneous; and
    • wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.
  • The complaint reserves the right to assert other claims Compl. Prayer for Relief, a.

U.S. Patent No. 10,426,743 - "Topical pharmaceutical compositions"

  • Patent Identification: U.S. Patent No. 10,426,743, titled "Topical pharmaceutical compositions," issued on October 1, 2019 (the "'743 Patent").

The Invention Explained

  • Problem Addressed: Similar to the '160 Patent, the '743 Patent addresses the difficulty of formulating the chemically sensitive active ingredient tapinarof into a physically stable topical composition that does not irritate the skin and effectively delivers the drug Compl. Ex. 2, col. 1:21-48
  • The Patented Solution: The patent claims a homogenous topical pharmaceutical emulsion comprising tapinarof, an oil phase, a water phase, a surfactant, and an antioxidant. The key inventive concept is the solubilization of the active ingredient within the oil phase of the emulsion, which enhances stability and delivery Compl. Ex. 2, abstract Compl. Ex. 2, col. 2:47-51
  • Technical Importance: By creating a stable formulation, the invention facilitates the practical use of tapinarof for treating key dermatological conditions like psoriasis and inflammation Compl. Ex. 2, col. 1:52-56

Key Claims at a Glance

  • The complaint asserts infringement of one or more claims of the '743 Patent Compl. ¶52
  • Independent claim 1 recites:
    • A method of treating an inflammatory disease or disorder in a patient in need thereof, comprising administering a topical pharmaceutical oil-in-water emulsion composition;
    • The composition comprises an effective amount of tapinarof, an oil phase, a water phase, a surfactant, and an antioxidant;
    • Wherein the tapinarof is solubilized in the oil phase;
    • Wherein the oil phase is substantially free of petrolatum and mineral oil; and
    • Wherein the average droplet size of the oil phase is from about 0.1 microns to about 35 microns.
  • The complaint reserves the right to assert other claims Compl. Prayer for Relief, c.

Multi-Patent Capsules

  • U.S. Patent No. 10,647,649: Titled "Process for preparing tapinarof," issued May 12, 2020 Compl. ¶24 This patent appears to cover a novel manufacturing process for tapinarof. The complaint alleges that Encube's ANDA Product, if manufactured, will infringe one or more claims Compl. ¶60
  • U.S. Patent No. 11,458,108: Titled "Topical pharmaceutical compositions," issued October 4, 2022 Compl. ¶25 This patent relates to compositions of tapinarof. The complaint alleges Encube's ANDA Product will infringe because it is designed to be bioequivalent to VTAMA and must copy its formulation Compl. ¶¶41-42
  • U.S. Patent No. 11,497,718: Titled "Use of tapinarof for the treatment of atopic dermatitis," issued November 15, 2022 Compl. ¶26 This patent covers a method of using tapinarof to treat atopic dermatitis. The complaint alleges that the proposed label for Encube's ANDA Product will induce infringement of this method patent Compl. ¶76, even though it also alleges Encube is carving out the atopic dermatitis indication Compl. ¶43
  • U.S. Patent No. 11,590,088: Titled "Use of tapinarof for the treatment of chronic plaque psoriasis," issued February 28, 2023 Compl. ¶27 This patent covers a method of using tapinarof to treat psoriasis. The complaint alleges that the proposed label for Encube's ANDA Product, which seeks a psoriasis indication, will induce infringement Compl. ¶83
  • U.S. Patent No. 11,597,692: Titled "Process for preparing tapinarof," issued March 7, 2023 Compl. ¶28 This patent appears to cover a novel manufacturing process for tapinarof. The complaint alleges that Encube's ANDA Product, if manufactured, will infringe one or more claims Compl. ¶88
  • U.S. Patent No. 11,612,573: Titled "Topical pharmaceutical compositions," issued March 28, 2023 Compl. ¶29 This patent relates to compositions of tapinarof. The complaint alleges Encube's ANDA Product will infringe because it is designed to be bioequivalent to VTAMA and must copy its formulation Compl. ¶41 Compl. ¶42
  • U.S. Patent No. 11,617,724: Titled "Topical pharmaceutical compositions," issued April 4, 2023 Compl. ¶30 This patent relates to compositions of tapinarof. The complaint alleges Encube's ANDA Product will infringe because it is designed to be bioequivalent to VTAMA and must copy its formulation Compl. ¶41 Compl. ¶42
  • U.S. Patent No. 11,622,945: Titled "Topical pharmaceutical compositions," issued April 11, 2023 Compl. ¶31 This patent relates to compositions of tapinarof. The complaint alleges Encube's ANDA Product will infringe because it is designed to be bioequivalent to VTAMA and must copy its formulation Compl. ¶41 Compl. ¶42
  • U.S. Patent No. 11,938,099: Titled "Use of tapinarof for the treatment of atopic dermatitis," issued March 26, 2024 Compl. ¶32 This patent covers a method of using tapinarof to treat atopic dermatitis. The complaint alleges that the proposed label for Encube's ANDA Product will induce infringement of this method patent Compl. ¶118
  • U.S. Patent No. 12,569,453: Titled "Use of tapinarof for the treatment of atopic dermatitis," issued March 10, 2026 Compl. ¶33 This patent covers a method of using tapinarof to treat atopic dermatitis. The complaint alleges that the proposed label for Encube's ANDA Product will induce infringement of this method patent Compl. ¶125

III. The Accused Instrumentality

Product Identification

  • The accused instrumentality is Defendant Encube's Abbreviated New Drug Application (ANDA) No. 218781 and the corresponding generic drug product ("Encube's ANDA Product") Compl. ¶1

Functionality and Market Context

  • Encube's ANDA Product is a 1% tapinarof topical cream intended for the treatment of plaque psoriasis Compl. ¶41 The complaint alleges that to gain FDA approval as a generic, Encube's ANDA Product must be bioequivalent to the reference listed drug, VTAMA Compl. ¶39 This requires the generic product to have the same active ingredient, dosage form, strength, and administration method as VTAMA Compl. ¶39 Furthermore, the complaint alleges that demonstrating bioequivalence for a topical formulation requires showing no significant difference in ingredients and that the product has the same physicochemical and structural attributes, including an "equivalent rate of tapinarof release" Compl. ¶42 The complaint notes that Encube's product label will be a copy of VTAMA's label, with the atopic dermatitis indication "carved out" Compl. ¶43 No probative visual evidence provided in complaint.

IV. Analysis of Infringement Allegations

'160 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A topical pharmaceutical oil-in-water emulsion composition comprising: 3,5-dihydroxy-4-isopropyl-trans-stilbene... The complaint alleges Encube's ANDA Product contains 1% tapinarof, which is the chemical name for the claimed active ingredient. ¶41 col. 1:30-38
an oil phase comprising medium chain triglycerides of a carbon length from six to twelve carbons... The complaint alleges the ANDA product is designed to copy the patented VTAMA formulation and must be bioequivalent, which suggests it will contain the requisite oil phase components. ¶41; ¶42 col. 12:15-24
a water phase The ANDA product is a topical cream, which implies the presence of an aqueous phase as part of an oil-in-water emulsion. ¶41 col. 12:40-50
a surfactant The ANDA product is a topical cream formulated as an emulsion, which implies the presence of a surfactant to stabilize the oil and water phases. ¶41 col. 12:51-65
a dermatologically acceptable excipient The complaint alleges the ANDA Product contains inactive ingredients designed to copy the patented VTAMA formulation. ¶41 col. 15:35-47
wherein the ... stilbene ... is solubilized in the oil phase... The complaint alleges that to demonstrate bioequivalence, the ANDA product must have the same physicochemical attributes as VTAMA, which Plaintiffs allege includes having the active ingredient solubilized in the oil phase. ¶42; ¶40 col. 3:1-15
wherein the oil phase is substantially free of petrolatum and mineral oil The complaint alleges Encube's product is bioequivalent to VTAMA, which itself is alleged to be formulated according to the patented invention that requires being substantially free of petrolatum and mineral oil. ¶42; ¶40 col. 2:45-51
wherein the oil-in-water emulsion is homogeneous Plaintiffs allege that to be bioequivalent, Encube's ANDA Product must have the same physicochemical and structural attributes as VTAMA, which is allegedly a homogeneous emulsion. ¶42; ¶40 col. 2:39-44

'743 Patent Infringement Allegations

Claim Element (from Independent Claim 1) Alleged Infringing Functionality Complaint Citation Patent Citation
A method of treating an inflammatory disease or disorder ... comprising administering to said patient a topical pharmaceutical oil-in-water emulsion composition... The complaint alleges Encube's ANDA product is a topical cream made for treating plaque psoriasis, an inflammatory disease. Its label will instruct this administration. ¶41; ¶43 col. 4:1-15
wherein the composition comprises an effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene... The complaint alleges Encube's ANDA Product contains 1% tapinarof, which is the chemical name for the claimed active ingredient. ¶41 col. 1:30-38
an oil phase The ANDA product is a topical cream, which implies the presence of an oil phase as part of an oil-in-water emulsion. ¶41 col. 10:35-43
wherein the 3,5-Dihydroxy-4-isopropyl-trans-stilbene ... is solubilized in the oil phase of the emulsion composition Plaintiffs allege that to be bioequivalent, Encube's ANDA Product must have the same physicochemical attributes as VTAMA, which is alleged to have the active ingredient solubilized in the oil phase. ¶42; ¶40 col. 3:1-15
wherein the oil phase is substantially free of petrolatum and mineral oil The complaint alleges Encube's product is bioequivalent to VTAMA, which itself is alleged to be formulated according to the patented invention that requires being substantially free of petrolatum and mineral oil. ¶42; ¶40 col. 2:45-51
  • Identified Points of Contention:
    • Evidentiary Questions: The complaint's infringement theory rests on the legal requirements for ANDA bioequivalence rather than on direct analysis of Encube's formulation. A central point of contention will be whether the evidence obtained through discovery confirms that Encube's ANDA Product actually meets every limitation of the asserted composition claims. The complaint acknowledges that its allegations "will likely have evidentiary support after a reasonable opportunity for further investigation" Compl. ¶40
    • Scope Questions: For the method-of-use patents, such as the '743 Patent and '088 Patent, a key question will be whether Encube's proposed product label will be found to actively induce infringement by medical practitioners and patients Compl. ¶55 This may involve analyzing the specific instructions for use on the proposed generic label.

V. Key Claim Terms for Construction

  • The Term: "homogeneous"

    • Context and Importance: This term is critical because the patentability of the formulations was based on solving the problem of non-uniform, unstable emulsions. Practitioners may focus on this term because a potential non-infringement defense could argue that Encube's product, while commercially acceptable, does not meet the specific definition of "homogeneous" required by the patent.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The specification describes a homogeneous emulsion in general terms, such as being "uniform in appearance" and contrasting with emulsions having "waxy" regions ('160 Patent, FIG. 1; '160 Patent, FIG. 2).
      • Evidence for a Narrower Interpretation: The specification provides quantitative metrics that could be linked to the term "homogeneous," such as having an "average droplet size of the discontinuous phase is less than about 35 microns" or even less than 1 micron ('160 Patent, col. 3:36-54). A party could argue these specific physical characteristics define what the patent means by "homogeneous."

  • The Term: "solubilized in the oil phase"

    • Context and Importance: This limitation is key to the invention's approach to stabilizing the active ingredient. A defendant might argue its formulation achieves bioequivalence without the tapinarof being "solubilized in the oil phase" to the extent required by the patent, perhaps by using a suspension or a different solvent system.
    • Intrinsic Evidence for Interpretation:
      • Evidence for a Broader Interpretation: The claim language itself does not quantify the degree of solubilization, which may support an interpretation that any meaningful amount of solubilization meets the limitation.
      • Evidence for a Narrower Interpretation: The specification explicitly states that in a preferred embodiment, "≥95% or ≥98% w/w of the active ingredient is solubilized in the oil phase of the emulsion" '160 Patent, col. 8:26-32 This provides a potential basis for arguing that "solubilized" requires near-complete dissolution in the oil phase.

VI. Other Allegations

  • Indirect Infringement: The complaint alleges inducement of infringement for the method-of-use patents (e.g., '743, '088 patents) Compl. ¶55 Compl. ¶83 The basis for this allegation is that Encube's ANDA Product, upon approval, will be sold with a package insert that copies the VTAMA label, thereby instructing and encouraging patients and medical practitioners to perform the patented methods of treatment Compl. ¶43 The complaint also alleges contributory infringement for the composition patents, stating the ANDA product is a material component especially made for infringing use and not suitable for substantial non-infringing use Compl. ¶49
  • Willful Infringement: While not pleaded as a separate count, the complaint lays the factual groundwork for willfulness. It alleges that Encube has had knowledge of the patents-in-suit since at least the date of its ANDA submission, citing Encube's knowledge of the Orange Book listings for VTAMA and its July 21, 2026 Notice Letter Compl. ¶47 Compl. ¶54 The complaint also notes Encube's prior IPR challenge to the '088 patent as evidence of knowledge Compl. ¶82

VII. Analyst's Conclusion: Key Questions for the Case

  1. A central evidentiary question will be one of technical equivalence: Will discovery confirm that Encube's ANDA product, formulated to be "bioequivalent" to VTAMA, actually practices the specific composition limitations-such as the degree of "homogeneity" and the extent to which tapinarof is "solubilized in the oil phase"-as defined and required by the asserted patents?
  2. A key legal issue will be one of inducement: For the method-of-use patents, does Encube's proposed product label, which carves out the atopic dermatitis indication, still contain sufficient instructions and encouragements to treat plaque psoriasis such that it will be found to induce infringement by patients and physicians?
  3. A significant question of claim construction will be whether terms like "homogeneous" are limited to the specific quantitative physical characteristics (e.g., droplet size) described in the patents' detailed descriptions, or if they will be given a broader, more qualitative meaning, which will directly impact the scope of the infringement analysis.